IPG Photonics Reports 15% Revenue Growth
The laser maker posted $287.5 million in third-quarter revenue and expects to close its Lumibird Medical acquisition in the fourth quarter.
Updated on Nov. 3, 2026 in Corporate Finance
IPG Photonics reported third-quarter 2026 revenue of $287.5 million, up 15% year over year, with net income of $20.3 million, or $0.47 per diluted share. The Marlborough, Massachusetts-based company also said it expects to close its acquisition of Lumibird Medical in the fourth quarter.
Why it matters
Growth was led by Advanced Solutions, where sales rose 33%, and by Industrial Solutions, where sales rose 12%, showing strength across both segments. The company's outlook and planned acquisition signal a push to expand its medical and advanced-applications business.
Third-quarter gross margin benefited from $5.0 million in net tariff refunds, and cash flow from operations reached $46 million against $17 million in capital expenditures. Fourth-quarter 2026 revenue guidance of $265 million to $295 million has not yet been tested by results.
The players
IPG Photonics
A Marlborough, Massachusetts-based maker of high-performance fiber lasers and amplifiers used in industrial manufacturing, medical, and advanced applications.
Lumibird Medical
The medical business being acquired by IPG Photonics, which is expected to increase the company's Advanced Solutions revenue.
The details
IPG Photonics said Industrial Solutions growth was driven by welding and additive manufacturing applications, while Advanced Solutions growth came from semiconductor and defense applications. Sales rose 33% in North America and 14% in Asia, but fell 1% in Europe.
Timeline
September 30, 2026: Third-quarter reporting period ended.
November 3, 2026: Third-quarter results released and earnings call held.
Fourth quarter 2026: Expected closing of the Lumibird Medical acquisition.
Market Dynamics
IPG's quarter reflects a split market in which industrial welding and additive manufacturing demand grew alongside semiconductor and defense applications, while Europe softened. The tariff refunds that lifted margins are a one-time item rather than a durable trend, so the company's underlying margin story depends on product cost reductions and fixed-cost absorption.
Investors weighing IPG Photonics shares will be watching whether fourth-quarter revenue lands within the $265 million to $295 million guidance and whether adjusted EBITDA reaches $33 million to $50 million. The Lumibird Medical deal's closing will also shape how the company's medical exposure appears in future reports.
The takeaway
IPG Photonics' growth came from both its industrial and advanced-applications businesses, but part of its margin gain came from one-time tariff refunds. Readers tracking the company should separate that temporary benefit from the underlying operating trend when reviewing its fourth-quarter results.
What happens next
IPG Photonics expects to close the Lumibird Medical acquisition in the fourth quarter of 2026, and the company will report fourth-quarter results after that period.
Further reading
For more on how company earnings shape the regional economy, explore Corporate Finance coverage.
Source note: This article includes information reported by The Manila times.
